ENTX Insider Trading

Insider Ownership Percentage: 10.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Entera Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Entera Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Entera Bio Share Price & Price History

Current Price: $2.24
Price Change: Price Decrease of -0.07 (-3.03%)
As of 02/19/2025 05:00 PM ET

This chart shows the closing price history over time for ENTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFeb$2.24Closing price on 02/19/25:

SEC Filings (Institutional Ownership Changes) for Entera Bio (NASDAQ:ENTX)

14.11% of Entera Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.28Mbought$37ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Entera Bio logo
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio

Today's Range

Now: $2.24
Low: $2.20
High: $2.42

50 Day Range

MA: $2.32
Low: $2.00
High: $2.72

52 Week Range

Now: $2.24
Low: $0.95
High: $3.35

Volume

49,452 shs

Average Volume

178,298 shs

Market Capitalization

$80.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Who are the company insiders with the largest holdings of Entera Bio?

Entera Bio's top insider shareholders include:
  1. Miranda Jayne Toledano (CEO)
  2. Sean Ellis (Director)
  3. Haya Taitel (Director)
Learn More about top insider investors at Entera Bio.

Who are the major institutional investors of Entera Bio?

Entera Bio's top institutional investors include:
  1. Knoll Capital Management LLC — 16.44%
  2. Schonfeld Strategic Advisors LLC — 1.77%
  3. Northern Trust Corp — 0.59%
  4. Perigon Wealth Management LLC — 0.41%
  5. Citadel Advisors LLC — 0.00%
  6. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Entera Bio stock.

Which major investors are selling Entera Bio stock?

Within the last quarter, ENTX stock was sold by these institutional investors:
  1. Schonfeld Strategic Advisors LLC
  2. Citadel Advisors LLC

Which major investors are buying Entera Bio stock?

During the last quarter, ENTX stock was bought by institutional investors including:
  1. Knoll Capital Management LLC
  2. Northern Trust Corp
  3. Perigon Wealth Management LLC
In the last year, these company insiders have bought Entera Bio stock:
  1. Miranda Jayne Toledano (CEO)
  2. Sean Ellis (Director)
  3. Haya Taitel (Director)
Learn More investors buying Entera Bio stock.